Abstract
Terguride (TER), a semisynthetic derivative of lisuride, has been found to display dopamine (DA) agonist and DA antagonist effects in animals, depending on the experimental model used. TER (2 mg/day) was compared to placebo in 41 fluctuating Parkinson's disease patients to test its effect on akinesia and dyskinesia. Mean hours 'off' decreased at weeks 6 and 12 (p <0.05) in the TER group but the overall difference from the placebo group was not significant. Only the TER group displayed a decrease over time in mean Columbia University Rating Scale total score 'on' and 'off' (p = 0.001 and p = 0.03, respectively). Duration of involuntary movements and resulting disability were not significantly different between patients on TER and those on placebo administration. In the overall evaluation, patients preferred TER (p = 0.01). Tolerance of TER was very good in all but one patient whose wearing-off increased, no one dropped out because of side effects. This 3-month double-blind study showed that TER, added to stable doses of L-dopa, may have slight antiparkinsonian efficacy.
| Original language | English |
|---|---|
| Pages (from-to) | 463-465 |
| Number of pages | 3 |
| Journal | Movement Disorders |
| Volume | 8 |
| Issue number | 4 |
| Publication status | Published - 1993 |
Fingerprint
Keywords
- Long-term L-dopa syndrome
- Parkinson's disease
- Terguride
ASJC Scopus subject areas
- Clinical Neurology
Cite this
Terguride in fluctuating parkinsonian patients : A double-blind study versus placebo. / Pacchetti, C.; Martignoni, E.; Bruggi, P.; Godi, L.; Aufdembrinke, B.; Miltenburger, C.; Voet, B.; Nappi, G.
In: Movement Disorders, Vol. 8, No. 4, 1993, p. 463-465.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Terguride in fluctuating parkinsonian patients
T2 - A double-blind study versus placebo
AU - Pacchetti, C.
AU - Martignoni, E.
AU - Bruggi, P.
AU - Godi, L.
AU - Aufdembrinke, B.
AU - Miltenburger, C.
AU - Voet, B.
AU - Nappi, G.
PY - 1993
Y1 - 1993
N2 - Terguride (TER), a semisynthetic derivative of lisuride, has been found to display dopamine (DA) agonist and DA antagonist effects in animals, depending on the experimental model used. TER (2 mg/day) was compared to placebo in 41 fluctuating Parkinson's disease patients to test its effect on akinesia and dyskinesia. Mean hours 'off' decreased at weeks 6 and 12 (p <0.05) in the TER group but the overall difference from the placebo group was not significant. Only the TER group displayed a decrease over time in mean Columbia University Rating Scale total score 'on' and 'off' (p = 0.001 and p = 0.03, respectively). Duration of involuntary movements and resulting disability were not significantly different between patients on TER and those on placebo administration. In the overall evaluation, patients preferred TER (p = 0.01). Tolerance of TER was very good in all but one patient whose wearing-off increased, no one dropped out because of side effects. This 3-month double-blind study showed that TER, added to stable doses of L-dopa, may have slight antiparkinsonian efficacy.
AB - Terguride (TER), a semisynthetic derivative of lisuride, has been found to display dopamine (DA) agonist and DA antagonist effects in animals, depending on the experimental model used. TER (2 mg/day) was compared to placebo in 41 fluctuating Parkinson's disease patients to test its effect on akinesia and dyskinesia. Mean hours 'off' decreased at weeks 6 and 12 (p <0.05) in the TER group but the overall difference from the placebo group was not significant. Only the TER group displayed a decrease over time in mean Columbia University Rating Scale total score 'on' and 'off' (p = 0.001 and p = 0.03, respectively). Duration of involuntary movements and resulting disability were not significantly different between patients on TER and those on placebo administration. In the overall evaluation, patients preferred TER (p = 0.01). Tolerance of TER was very good in all but one patient whose wearing-off increased, no one dropped out because of side effects. This 3-month double-blind study showed that TER, added to stable doses of L-dopa, may have slight antiparkinsonian efficacy.
KW - Long-term L-dopa syndrome
KW - Parkinson's disease
KW - Terguride
UR - http://www.scopus.com/inward/record.url?scp=0027380410&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027380410&partnerID=8YFLogxK
M3 - Article
VL - 8
SP - 463
EP - 465
JO - Movement Disorders
JF - Movement Disorders
SN - 0885-3185
IS - 4
ER -